Redx Pharma
Redx is a UK biotechnology Group whose shares are traded on AIM [AIM:REDX]. Redx is focused on creating and developing first-in-class, or potentially best-in-class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.
Sector
Biopharmaceuticals
Strategies
Crossover
Status
Active
Website
www.redxpharma.com
Related Articles
Redx Pharma plc Placing to raise c.£25.5 million and Open Offer to raise up to £2.2 million and Conversion of loan notes
Redx Pharma announces appointment of leading oncology drug developer, Dr Jane Robertson, as Chief Medical Officer
Redx announces new research collaboration with Jazz Pharmaceuticals to discover and develop two targeted cancer therapies
Appointment of Non-Executive Director and changes to Board committees
Redx signs out licensing agreement with AstraZeneca
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.